First Citizens Bank & Trust Co. Has $1.74 Million Holdings in Quest Diagnostics Inc (DGX)
First Citizens Bank & Trust Co. decreased its position in shares of Quest Diagnostics Inc (NYSE:DGX) by 14.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,611 shares of the medical research company’s stock after selling 3,009 shares during the period. First Citizens Bank & Trust Co.’s holdings in Quest Diagnostics were worth $1,735,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently bought and sold shares of the company. WFG Advisors LP increased its position in Quest Diagnostics by 45.3% during the second quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock valued at $107,000 after acquiring an additional 301 shares during the last quarter. Sun Life Financial INC increased its position in Quest Diagnostics by 14,142.9% during the second quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock valued at $111,000 after acquiring an additional 990 shares during the last quarter. Acrospire Investment Management LLC increased its position in Quest Diagnostics by 300.0% during the second quarter. Acrospire Investment Management LLC now owns 1,600 shares of the medical research company’s stock valued at $178,000 after acquiring an additional 1,200 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Quest Diagnostics during the second quarter valued at $180,000. Finally, Parametrica Management Ltd bought a new position in Quest Diagnostics during the third quarter valued at $206,000. Institutional investors and hedge funds own 88.84% of the company’s stock.
In related news, EVP J. E. Davis sold 63,880 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $98.68, for a total value of $6,303,678.40. Following the completion of the sale, the executive vice president now directly owns 101,423 shares of the company’s stock, valued at $10,008,421.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.75% of the stock is owned by corporate insiders.
DGX has been the topic of a number of analyst reports. Raymond James Financial reiterated a “market perform” rating on shares of Quest Diagnostics in a research report on Monday, September 25th. Goldman Sachs Group lowered shares of Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and lowered their target price for the company from $121.00 to $113.00 in a research note on Tuesday, October 10th. Canaccord Genuity reissued a “buy” rating and set a $118.00 target price on shares of Quest Diagnostics in a research note on Wednesday, September 13th. Zacks Investment Research lowered shares of Quest Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, October 27th. Finally, Citigroup lowered their target price on shares of Quest Diagnostics from $110.00 to $98.00 and set a “neutral” rating for the company in a research note on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $106.20.
Shares of Quest Diagnostics Inc (NYSE:DGX) opened at $100.37 on Thursday. Quest Diagnostics Inc has a one year low of $90.10 and a one year high of $112.96. The firm has a market cap of $13,680.00, a PE ratio of 20.91, a P/E/G ratio of 2.05 and a beta of 0.60. The company has a quick ratio of 1.37, a current ratio of 1.47 and a debt-to-equity ratio of 0.78.
Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Thursday, October 19th. The medical research company reported $1.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.04. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.53%. The company had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.92 billion. During the same period in the prior year, the firm earned $1.37 earnings per share. The firm’s revenue for the quarter was up 2.4% compared to the same quarter last year. analysts anticipate that Quest Diagnostics Inc will post 5.65 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 9th will be paid a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a yield of 1.79%. The ex-dividend date is Monday, January 8th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 37.50%.
WARNING: “First Citizens Bank & Trust Co. Has $1.74 Million Holdings in Quest Diagnostics Inc (DGX)” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/first-citizens-bank-trust-co-has-1-74-million-holdings-in-quest-diagnostics-inc-dgx/1802433.html.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with Analyst Ratings Network's FREE daily email newsletter.